Introduction {#S1}
============

Celiac disease (CD) is a permanent intolerance to ingested gluten that results in immunologically mediated inflammatory damage to the small intestinal mucosa. CD must always be considered when dealing with children manifesting growth failure. The prevalence of CD among children with short stature in Europe is approximately 0.05--0.2% of the general population, reaching 1 in 300 in western Ireland. In Italy the prevalence is 59.1%^[@R1]^ whereas in Spain it is 0.56%^[@R2]^ and in western New York 4.0%.^[@R3]^ There has been no study conducted to assess its prevalence in children with short stature in Saudi Arabia.

Classically infants with CD present with impaired growth, diarrhea, and abdominal distension. Usually atypical presentation is seen in older children, who often have no overt features of malabsorption.^[@R4]^ Extra-intestinal manifestations such as short stature, delayed puberty, dental enamel defects, and arthralgia may occur as a monosymptomatic manifestation.^[@R5]^ The diagnosis of CD was based on clinical symptoms, positive antibodies, and a small bowel biopsy.^[@R6],[@R7]^ Histological evidence of CD was reported according to the Oberhuber classification.^[@R8]^

Our aim in the present study is to assess the prevalence of CD among Saudi children with short stature who have no gastrointestinal symptoms, and to determine whether celiac serology can detect all cases of CD or if an intestinal biopsy should be performed for any case of short stature.

Materials and Methods {#S2}
=====================

A total of 91 children with a height less than the 5^th^ centile adjusted for their age and gender were studied. All children were followed up in the Department of Pediatrics at King Khalid University Hospital from the period of August 2002 to December 2008. Any child with gastrointestinal symptoms was excluded from the study. All children with etiological factors known to produce growth failure had also been excluded; for example chromosomal anomalies, fetal growth failure, and chronic illnesses. Selection criteria are shown in [Table 1](#T1){ref-type="table"}.

Table 1Selection criteria.1All short children, height \<5^th^ centile for age and gender2No gastrointestinal symptoms3Normal endocrine work-up (e.g. normal GH response, normal TFT)4No evidence of chronic disorders5Normal karyotype for female6Negative history of genetic short stature

All children had undergone an extensive endocrine work-up that included growth hormone (GH), free-thyroxin (FT~4~), thyroid stimulating hormone (TSH), glucose, electrolytes, venous blood gas, and urine pH assessments. The routine GH stimulation test using two biochemical (either clonidine and glucagon or insulin-induced hypoglycemia as a secretagogue) and two physiological (post-exercise and during sleep) assessments was performed. Patients were considered not to be GH deficient when the peak GH value during the stimulation test or the physiological test was \>10 ng/dL. Other routine investigations, such as hemoglobin level \[MCV, MCHC, total protein, serum albumin, coagulation profile, calcium, phosphorous, and alkaline phosphatase (ALP)\] were done. Stool investigations for giardiasis were done for all patients. Bone age was determined using the Greulich and Pyle atlas.^[@R9]^ Pubertal stages were evaluated according to Tanner.^[@R10]^ Mid-parental height was calculated for each child\'s parents to exclude genetic causes of short stature, using the standard formula.^[@R11]^

Anti-endomysial and anti-tissue transglutaminase screening tests for CD were performed for the patients. When no cause of short stature was found, upper digestive endoscopies and small bowel biopsies was done for all children. The biopsy specimens were taken from the third part of the duodenum.

The results of the children\'s heights before and after the gluten-free diet were expressed as a z-score.

Results {#S3}
=======

Ten of the ninety-one patients had a positive endoscopic intestinal biopsy with an increase in the crypt height and increase in intra-epithelial lymphocyte (IEL) numbers up to \>40 IEL/100EC, Type 3C, according to the Oberhuber classification, indicating CD (group 1; N=10). Seventy-six children had a normal endoscopic intestinal biopsy, and five had mild villous atrophy with normal crypts, Type 3A according to this classification, and were considered to have potential CD (Group 2; N=5). Therefore, the prevalence of well-diagnosed CD among children of short stature in this study was 10.9% while 4.3% was diagnosed as having potential CD.

CD in our study affected six males and four females, thus the prevalence was equal in males and females. The mean values for chronological age, height, weight, bone age, as well as pubertal stage were not significantly different between patients with CD and non-celiacs (P\>0.05). The results of serum calcium, phosphate, alkaline phosphatase, total protein, albumin assays, and hormonal tests were also not significantly different. Tests for celiac antibodies (anti-endomysial and anti-tissue transglutaminase) were done for all the patients and were strongly positive for ten children, who were confirmed histologically to have CD, Type 3C. Five patients were IgG positive for anti-endomysial antibody, shown histologically to be Type 3A.

All children diagnosed to have CD and potential CD were kept on a gluten-free diet. Patients were followed-up every six months and showed improvement in growth rate. Four of them had complete catch-up in growth after one year on a gluten-free diet ([Table 2](#T2){ref-type="table"}). The z-score for height before diagnosis was 2.14011±1.67487 while it was 1.84149±1.83677 one year after starting the gluten-free diet.

Table 2Age, gender, serology, histology, and height of children at the initial presentation and follow-up of height, one year on a gluten-free diet.Age (years)GenderSerologyHistologyHt 1 (cm)Ht1 z-scoreHt2 (cm)Ht2 z-score4.5M++Type 3C100.00−0.74439114.50−0.1556211F++Type 3C126.001.67487134.001.836776.5M++Type 3C106.00−0.18610112.80−0.329315F++Type 3C98.00−0.93048110.00−0.6154010F++Type 3C117.000.83744125.000.9172110F++Type 3C117.000.83744125.000.917215M++Type 3C102.00−0.55829125.00−0.615404M++Type 3C102.00−0.55829110.00−0.615407F++Type 3C85.00−2.1401198.00−1.841497F++Type 3C107.00−0.09305115.00−0.104539M+Type 3A113.000.46524120.000.406346F+Type 3A104.00−0.37219110.00−0.615408M+Type 3A110.000.18610107.00−0.9219212F+Type 3A119.001.02353127.001.1215512F+Type 3A119.001.02353127.001.12155Z-score2.14011±1.674871.84149±1.83677[^1][^2]

[Table 2](#T2){ref-type="table"} shows age, gender, serology, histology, and height of children at the initial presentation and on follow-up of height one year on the gluten-free diet, as a z-score.

Discussion {#S4}
==========

This series shows a significant number of cases of CD and potential CD (10.9% and 4.3%) among Saudi children with short stature, who do not have underlying causes for their short statures. The prevalence of CD in children with short stature has been studied in different regions of the world. It ranged from 0.05--59.1% depending on the region of the study.^[@R1],[@R3]^ In reviewing the literature we found no single parameter suggestive of CD in children with short-stature.^[@R12]--[@R15]^ This supports our data in this study.

None of the biochemical and hormonal measurements was positive in our patients. The pathogenesis of short stature as a monosymptomatic manifestation in children with CD is not known. A review of the literature showed that there are reasons to suggest that nutritional deficiencies can result in growth failure associated with changes in hormonal status.^[@R1]^ The hormonal abnormalities in these data included low levels of insulin-like growth factor-1 (IGF-I), which occurs after prolonged exposure to gluten, and poor growth hormone release in stimulatory tests.^[@R16]^ Other endocrine abnormalities that can occur in CD included secondary hypopituitarism probably caused by severe malnutrition and mainly found in longstanding CD, hypogonadism and delayed puberty, reversed insensitivity to androgens, elevated plasma testosterone, free testosterone index, and raised plasma luteinizing hormone.^[@R1],[@R17]^ All children included in our study had no gastrointestinal symptoms or malnutrition and GH and thyroid hormone secretion were normal.

The ultimate adult height will improve if the treatment of CD is started early; however, there will be a slight negative effect of the disease on growth.^[@R18]^ Most of our children in this study who were followed up after one year showed an increase in their heights. Height and weight velocities had their maximum rates during the first year after initiation of the gluten-free diet, but the catch-up growth was incomplete over three years, the final height seemingly influenced mainly by familial characteristics.^[@R18]^

We concluded that CD is prevalent among Saudi children with short stature. The fact that there was no difference between CD and non- CD clinical, biochemical, and hormonal tests indicates that it is important to do anti-endomysial and anti-tissue transglutaminase antibody tests to investigate all children with short stature for CD. In addition, it is important to do a small bowel biopsy for children with short stature, irrespective of the result of celiac serology, in Saudi Arabia and all over the world.
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[^1]: 1.At the initial presentation. 2.Follow-up of height after one year on a gluten-free diet. Histology according to the Oberhuber classification^[@R8]^;

[^2]: (+), positive; (−), negative; ++, anti-tissue transglutaminase; +, anti-endomysial IgG.
